Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Research uncovers how inhibiting interactions between cyclin A and cyclin B and their key binding partners, E2F and MYT1, selectively kills E2F-high tumor cells Circle Pharma’s oral first-in-class ...
Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Circle Pharma, a clinical-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results